Gland Pharma has announced its Q3 financial results, reporting strong year-on-year growth across key operational and profitability metrics, supported by healthy demand for injectable formulations in global markets.
For the quarter, Gland Pharma posted a 27.5% YoY jump in net profit, which rose to ₹261.4 crore compared with ₹205 crore in the corresponding period last year. The improvement in bottom-line performance reflects higher scale of operations and improved execution across its core product segments.
Revenue for the quarter increased by 22.5% YoY to ₹1,695 crore, up from ₹1,384 crore in Q3 of the previous financial year. The growth was driven by steady traction in regulated markets, expansion of product filings, and sustained customer demand for sterile injectables.
On the operating front, EBITDA grew 20.8% YoY to ₹434.9 crore, compared with ₹360 crore in the year-ago quarter. Despite the rise in operating profit, EBITDA margin moderated slightly to 25.6% from 26% YoY, indicating mild pressure from costs and mix changes during the quarter.
